PMV Pharmaceuticals (PMVP) Proxy Filing summary

Executive summary

• The annual meeting will be held virtually on June 5, 2025, with voting available online, by phone, or by mail.

• Stockholders will vote on the election of two Class II directors, a non-binding say-on-pay proposal, and ratification of the external auditor.

• Proxy materials are distributed primarily online to reduce costs and environmental impact.

• The record date for voting eligibility is April 8, 2025, with 51,951,761 shares outstanding.

Voting matters and shareholder proposals

• Proposals include electing Arnold Levine, Ph.D. and Charles M. Baum, M.D., Ph.D. as Class II directors, approving executive compensation, and ratifying Ernst & Young LLP as auditor.

• Board recommends voting FOR all proposals.

• Shareholders may submit proposals or director nominations for the 2026 meeting by specified deadlines.

Board of directors and corporate governance

• Board consists of seven members divided into three staggered classes.

• Six of seven directors are independent; CEO is not independent.

• Board committees include audit, compensation, and nominating/governance, each with written charters and independent members.

• Board leadership is separated between the CEO and the chairperson.

• Board diversity matrix and director qualifications are disclosed.